Inhaladores de acción larga

Diego Severiche Hernández; Diego F Severiche Bueno; Daniel Felipe Severiche Bueno; María Teresa Vargas Cuervo

doi:10.30789/rcneumologia.v29.n2.2017.265

PDF

FLIP

Cómo citar

1.

Severiche Hernández D, Severiche Bueno DF, Severiche Bueno DF, Vargas Cuervo MT. Inhaladores de acción larga. rev. colomb. neumol. [Internet]. 10 de mayo de 2018 [citado 20 de abril de 2024];29(2):28-3. Disponible en: https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/265

Publicado: May 10, 2018

Doi

https://doi.org/10.30789/rcneumologia.v29.n2.2017.265

Dimensions

PlumX

Número

Vol. 29 Núm. 2 (2017)

Sección

Reportes de casos

Términos de la licencia (VER)

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Diego Severiche Hernández

Médico Internista, Neumólogo e Intensivista. Especialista en Bioética y Educación Médica. Docente, Facultad de Medicina, Universidad de La Sabana. Médico especialista adscrito de la Clínica del Country, Clínica Shaio, Bogotá. Médico especialista de la Unidad de Cuidado Intensivo del Hospital San Rafael de Tunja. Médico especialista de la Unidad de Cuidado Intensivo e Intermedio del Hospital Universitario de la Samaritana. Bogotá, Colombia.

Diego F Severiche Bueno

Residente I de Medicina Interna, Facultad de Medicina, Universidad de La Sabana. Bogotá, Colombia.

Daniel Felipe Severiche Bueno

Estudiante de X semestre, Facultad de Medicina, Universidad de La Sabana. Bogotá, Colombia.

María Teresa Vargas Cuervo

Médico Interno, Facultad de Medicina, Pontificia Universidad Javeriana. Bogotá, Colombia

Resumen

Hoy día, en el mundo, los inhaladores de acción larga son herramientas fundamentales para el tratamiento de las enfermedades broncoobstructivas. Su uso está avalado por consensos internacionales ampliamente difundidos y reconocidos mundialmente, como son las Guías GINA 2017 y las Guías GOLD 2017, entre otros. En Colombia, desde hace varios años, la comunidad médica dispone de varias presentaciones comerciales de inhaladores solos o en diferentes combinaciones. Por tanto, se consideró pertinente realizar una revisión de los conceptos fisiológicos fundamentales, de los principios farmacológicos, de los mecanismos de acción, de la farmacodinamia y farmacocinética. Igualmente, con base en la evidencia disponible al momento de la realización de este artículo, se revisarán las indicaciones clínicas para su uso en las diferentes enfermedades broncoobstructivas.

Palabras clave:

broncodilatadores

anticolinérgicos

betaagonistas

mecanismo de acción

farmacodinamia

farmacocinética

Descargas

Los datos de descargas todavía no están disponibles.

Referencias (VER)

Lindenauer PK, Shieh MS, Pekow PS, Stefan MS. Use and outcomes associated with long-acting bronchodilators among patients hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(8):1186-94. DOI: 10.1513/ AnnalsATS.201407-311OC.

Fink JB, Colide GL, Hodder R. Inhaler devices for patients with COPD. COPD. 2013;10(4):523-35. DOI: 10.3109/15412555.2012.761960.

Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:24959. DOI: https://doi.org/10.1378/chest.125.1.249.

O ́Byrne PM, Sears MR. Inhaled β 2 agonist. En: Adkinson N, Bochner B, Burks A, Busse W, Holgate S, Lemanske R, et al (editores). Middleton’s allergy principles and practice. 8 a edición. Philadelphia: Saunders Elsevier. 2014. p. 1534-41.

Lands AM, Luduena FP, Buzzo HJ. Differentiation of receptors responsive to isoproterenol. Life Sci. 1967;6(21):2241-9. DOI: https://doi.org/10.1016/0024-3205(67)90031-8.

Kraft WK, Leone FT. Asthma and chronic obstructive pulmonary disease. En: Waller D, Sampson T. Pharmacology and therapeutics. 5.a edición. Filadelfia: Saunders Elsevier; 2009. p. 417-34.

Matera M, Calzetta L, Cazzola M. β-adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. Drugs. 2013;73(15):1653-63. DOI: 10.1007/s40265-013-0120-5.

Mohamed MH, Lima JJ, Eberle LV, Self TH, Johnson JA. Effects of gender and race on albuterol pharmacokinetics. Pharmacotherapy. 1999;19:157-61. DOI: 10.1592/phco.19.3.157.30925.

Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? 2013;7(2):816. DOI: 10.1177/1753465812465784.

Kempford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256-64. DOI: 10.1016/j.pupt.2012.12.001.

Global Initiative for Asthma (GINA). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017. Disponible en: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2016. Disponible en: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/

Cazzola M, Beeh K, Price D, Roche N. Assessing the clinical value of fast onset and sustained duration of action of longacting bronchodilators for COPD. Pulm Pharmacol Ther. 2015;31:68-78. DOI: 10.1016/j.pupt.2015.02.007.

Murphy L, Rennard S, Donohue J, Molimard M, Dahl R, Beeh K, et al. Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs. 2014;74(14):1635-57. DOI: 10.1007/s40265-014-0284-7.

Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-weeks studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629-45. DOI: 10.2147/COPD.S61717.

Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat. Int J Chron Obstruct Pulmon Dis. 2014;9:697-714. DOI: 10.2147/COPD.S62502.

Lange P, Aumann JL, Hamilton A, Tetzlaff K, Ting N, Derom E. The 24-hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med. 2014;4:196. DOI: 10.4172/2161-105X.1000196.

Kunz C, Luedtke D, Unseld A, Hamilton A, Halabi A, Wein M, et al. Pharmacokinetics and safety of olodaterol administered with the Respimat soft mist inhaler in subjects with impaired hepatic or renal function. Int J Chron Obstruct Pulmon Dis. 2016;11:585-95. DOI: 10.2147/COPD.S94234.

Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Betaagonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002;165:1353-8. DOI: 10.1164/rccm.2109060.

Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989;140(3):586-92. DOI: 10.1164/ajrccm/140.3.586.

Larj MJ, Bleecker ER. Effects of beta2-agonists on airway tone and bronchial responsiveness. J Allergy Clin Immunol. 2002;110(6):S304-12. DOI: https://doi.org/10.1067/mai.2002.130045.

Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest. 2003;123(6):1817-24. DOI: 10.1378/chest.123.6.1817.

Murray JJ. Cardiovascular risks associated with betaagonist therapy. Chest. 2005;127:2283-5. DOI: 10.1378/chest.127.6.2283-a.

Gersho A, Croxford R, Calzavara T, To T, Stanbrook M, Upshur R, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175-85. DOI: 10.1001/jamainternmed.2013.1016.

Crane J, Burgess C, Beasley R. Cardiovascular and hypokalemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax. 1989;44:136-40. DOI: 10.1136/thx.44.2.136.

Nathan RA, Seltzer JM, Kemp JP, Chervinsky P, Alexander WJ, Liddle R, et al. Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol. 1995;75:243-8.

Bremner P, Woodman K, Burgess C, Crane J, Purdie G, Pearce N, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J. 1993;6(2):204-10.

Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Chest. 1996;110(1):42-7. DOI: https://doi.org/10.1378/chest.110.1.42.

Peters SP, Dykewicz MS. Anticholinergic Therapies. En: Adkinson N, Bochner B, Burks A, Busse W, Holgate S, Lemanske R, et al (editores). Middleton’s allergy principles and practice. 8 a edición. Philadelphia: Saunders Elsevier. 2014. p. 1552-66.

Laitinen A, Partanen M, Hervonen A, Laitinen LA. Electron microscopic study on the innervation of the human lower respiratory tract: evidence of adrenergic nerves. Eur J Respir Dis. 1985;67(3):209-15.

Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs. 2001;10:733-74. DOI: https://doi.org/10.1517/13543784.10.4.733

Kerwin E, Herbert J, Gallagher N, Martin C, Overen T, Alagappan VK, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106-14. DOI: 10.1183/09031936.00040712.

D ́urzo A, Ferguson GT, van Noord JA, Hirata KMC, Horton R, et al. Efficacy and safety of once daily NVA237 in patients with moderate to severe COPD: the GLOW1 trial. Respir Res. 2011;12:156. DOI: 10.1186/1465-9921-12-156.

Miravitlles M, Beeh KM, Altman P. Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clin Invest. 2014;4(12):1095-11. DOI: 10.4155/cli.14.89.

Decramer M, Maltais F, Feldman G, Brooks J, Harris S, Meht R, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185(2):393-9. DOI: 10.1016/j.resp.2012.08.022.

Canadian Agency for Drugs and Technologies in Health. Aclidinium bromide (tudorza genuair): long-term maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease. Ottawa: CADTH Common Drug Reviews. 2015.

Jones PW, Singh DBED, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830-6. DOI: 10.1183/09031936.00225511.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54. DOI: 10.1056/NEJMoa0805800.

Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-50. DOI: 10.1001/jama.300.12.1439.

Food and Drug Administration (FDA). Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). Silver Spring, MD: Food and Drug Administration. 2008.

Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA’s conclusions. N Engl J Med. 2010;363(12):1097-9. DOI: 10.1056/NEJMp1008502.

Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4):1136-42. DOI: 10.1164/ajrccm.161.4.9903044.

Kalra L, Bone MF. The effect of nebulized bronchodilator therapy on intraocular pressures in patients with glaucoma. Chest. 1988;93(4):739-41. DOI: https://doi.org/10.1378/chest.93.4.73.

Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12-month study. Thorax. 2006;61(2):122-8. DOI: 10.1136/thx.2004.033266.

van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129(3):509-17. DOI: 10.1378/chest.129.3.509.

Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290(17):2301-12. DOI: 10.1001/jama.290.17.2301.

Di Martno M, Agababiti N, Bauleo L, Kirchmayer U, Cascini S, Pistelli R, et al. Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study. COPD. 2014;11(4):414-23. DOI: 10.3109/15412555.2013.839646.

Ramlal SK, Visser FJ, Hop WCJ, Dekhuijzen PNR, Heijdra YF. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD. Pulm Pharmacol Therapeutics. 2014;28(2):158-64. DOI: http://dx.doi.org/10.1016/j.pupt.2013.09.002.

Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;10:CD010177. DOI: 10.1002/14651858.CD010177.pub2.

Kliber A, Lynd LD, Sin DD. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res. 2010;11(1):56. DOI:10.1186/1465-9921-11-56.

Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149. DOI: 10.1186/1465-9921-11-149.

Santus P, Radovanovic D, Paggiaro P, Papi A, Sanduzzi A, Scichilone N, et al. Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. Eur J Intern Med. 2015;26(6):379-84. DOI: 10.1016/j.ejim.2015.05.001.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-89. DOI: 10.1056/NEJMoa063070.

Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, et al. Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis. Respir Res. 2013;14(1):100. DOI:10.1186/1465-9921-14-100.

Hanania NA, Fledman G, Zachgo W, Shim JJ, Crim C, Snaford L, et al. The efficacy and safety of the novel long acting B2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142:119-27. DOI: 10.1378/chest.11-2231.

Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538-46. DOI: 10.1016/j.rmed.2013.06.001.

Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317-26. DOI: 10.7326/0003-4819-143-5-200509060-00007.

Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2:CD002876. DOI: 10.1002/14651858.CD002876.pub2.

Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19(2):209-16. DOI: 10.1183/09031936.02.00238702.

Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3(1):127-36. DOI: https://doi.org/10.2147/COPD.S2389.

Vogelmeier C, Fabbri LM, Rabe KF, Beeh KM, Schmidt H, Metzdorf N, et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respir Med. 2013;107(1):75-83. DOI: 10.1016/j.rmed.2012.09.015.

Riaro-Sforza GG, Ridolo E, Riaro-Sforza E, Incorvaia C. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2014;9(1):23-33. DOI: https://doi.org/10.1586/17476348.2015.996133.

Ernst P, McIvor A, Ducharme FM, Boulet L, FitzGerald M, Chapman KR, et al. Safety and effectiveness of long-acting inhaled β-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med. 2006;145:692-4. DOI: 10.7326/0003-4819-145-9-200611070-00012.

Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2010;35(3):532-9. DOI: 10.1183/09031936.00153108.

Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley R. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26. DOI: https://doi.org/10.1164/rccm.200707-973OC.

Banerji D, Fogel R, Beeh M. Dual Bronchodilation for the treatment of Chronic obstructive pulmonary disease: a review of the latest clinical data. Clin Invest. 2014;4(6):511-33. DOI: 10.4155/cli.14.50.

Frampton JE. QVA149 (indacaterol/glycopyrronium fixeddose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014;74(4):465-88. DOI: 10.1007/s40265-014-0194-8.

Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D›Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomized double blind, parallel group study. Lancet Respir Med. 2013;1(1):51-60. DOI: 10.1016/S2213-2600(12)70052-8.

Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D›Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108(4):584-92. DOI: 10.1016/j.rmed.2014.01.006.

Wedzicha J, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double blind, parallel group study. Lancet Respir Med. 2013;1(3):199-209. DOI: 10.1016/S2213-2600(13)70052-3.

Mahler DA, Decramer M, D ́Urzo A, Worth H, White T, Alagappan VK, et al. Dual bronchodilation with QVA149 reduces patient reported dyspnea in COPD: the BLAZE study. Eur Respir J. 2014;43(6):1599-609. DOI: 10.1183/09031936.00124013.

Matera M, Rogliani P, Cazzola M. QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015;16:1079-90. DOI: 10.1517/14656566.2015.1032247.

Anzueto A, Decramer M, Kaelin T, Richard N, Tabberer M, Harris S. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD. Am J Respir Crit Care Med 2013;187:A4268.

Decramer M, Anzueto A, Kerwin E, Richar N, Crater G, Tabberer M, et al. Efficacy and safety of umeclinidium plus vilanterol tiotropium, vilanterol, or umeclinidium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-86. Doi: 10.1016/S2213-2600(14)70065-7.

US Food and Drug Administration. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term, oncedaily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) 2013.

Welte T, Vogelmeier C, Dahl R, Chapman KR, Rudolf M, Mehta R, et al. Once-daily QVA149 has a good safety profile in patients with COPD. Eur Respir J. 2013;42(57):143s-44s.

Ferguson GT, Barnes N, Mehta R, D ́Andrea P, Chen H, Banerji D. Cardio-and cerebrovascular safety of QVA149: results from a pooled analysis. Eur Respir J. 2013;42(57):878s.

D’Urzo A, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24week, randomized, placebo-controlled AUGMENT-COPD study. Respir Res. 2014;15(1):123. DOI: 10.1186/s12931014-0123-0.

Singh D, Jones P, Bateman E, Korn S, Serra C, Molins E, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORMCOPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178. DOI: 10.1186/1471-2466-14-178.

Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Longacting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev. 2007;1:CD001385. DOI: 10.1002/14651858.CD001385.pub2.

Nelson HS, Weiss ST, Bleecker ER, Yancey ST, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26. DOI: 10.1378/chest.129.1.15.

Donohue JF. Safety and efficacy of beta agonists. Respir Care. 2008;53:618-22.

Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519-26. DOI: 10.1164/rccm.200509-1519OC.

Bleecker ER, Emmett A, Crater G, Knobil K, Kalberg C. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther. 2008;21(4):682-8. DOI: 10.1016/j.pupt.2008.04.003.

Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, et al. Effect of β 2 -adrenergic receptor polymorphism on response to long-acting β 2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebocontrolled, crossover trial. Lancet. 2009;374(9703):1754-64. DOI: 10.1016/S0140-6736(09)61492-6.

US Food and Drugs Administration (FDA). Drug safety communication: new safety requirements for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). 2010.

Price D, Fromer L, Kaplan A, van der Molen T, Román-Rodríguez MR. Is there a rationale and role for long acting anticholinergic bronchodilators in asthma? NPJ Primary Care Resp Med. 2014;24:14023. DOI: 10.1038/npjpcrm.2014.23.

Magnussen H, Bugnas B, van-Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102(1):50-6. DOI: 10.1016/j.rmed.2007.08.003.

Iwamoto H, Yokoyama A, Shiota N, Shoda H, Haruta Y, Hattori N, et al. Tiotropium bromide is effective for severe asthma with non-eosinophilic phenotype. Eur Respir J. 2008;31(6):1379-80. DOI: 10.1183/09031936.00014108.

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is non-inferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128(2):315-22. DOI: 10.1016/j.jaci.2011.06.004.

Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715-26. DOI: 10.1056/NEJMoa1008770.

Kerstjens HA, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308-14. DOI: 10.1016/j.jaci.2011.04.039.

Citado por

Barra lateral del artículo